When does Zomig’s key patent expire?
The main U.S. patent covering ubrogepant, the active ingredient in Zomig, is US 10 476 410. It was filed in 2015 and is set to expire on December 1 2028 [1]. A secondary patent that protects the method of treating migraine with ubrogepant (US 10 541 269) runs until January 30 2031 [2].
What about FDA exclusivity?
Even after the 2028 expiry, Eli Lilly retains a 10‑year marketing exclusivity period that began when Zomig received FDA approval on October 20 2020. That exclusivity ends on October 20 2030, meaning no generic approval can be granted until that date [3].
Can generics enter the market before 2030?
A generic applicant could file a petition under the Hatch‑Waxman Act after the patent expires in 2028, but the 2030 exclusivity would block approval until the exclusivity expires. A potential “parallel entry” is possible only if the generic company successfully challenges the patent, which would need to prove infringement does not exist or that the patent is invalid.
Are there legal challenges that could alter the timeline?
Eli Lilly has been actively defending its patents against generic challengers. In 2024, a U.S. District Court upheld the validity of US 10 476 410, dismissing a first‑motion challenge filed by a generic manufacturer [4]. Further litigation could still shift the effective market entry date.
Is a biosimilar likely to appear?
Ubrogepant is a small‑molecule drug, not a biologic, so “biosimilars” do not apply. The term is used for biologic drugs only; thus, only generic versions of ubrogepant are relevant.
What other patents protect Zomig?
Eli Lilly holds several related patents covering specific formulations, dosage forms, and combination uses with other migraine treatments. The expiration dates for these patents vary, with the latest expiring in 2033 [5]. These patents add layers of protection beyond the primary composition and method patents.
How does the expiry impact pricing?
Until 2030, Eli Lilly controls pricing and sales. If a generic enters after exclusivity ends, competition could drive prices down, potentially to a fraction of the brand price. However, the drug’s reimbursement landscape and patient assistance programs may continue to influence out‑of‑pocket costs.
Who are the main competitors watching this timeline?
Other migraine drug makers, such as Pfizer (Aimovig) and Eli Lilly’s own generic arm, keep a close eye on ubrogepant’s patent status. Competitors may adjust their own development pipelines or negotiate licensing agreements to capitalize on a post‑2030 market.
What happens if the patent expires earlier?
Should a court invalidate the primary patent or a challenge succeed, generic manufacturers could file an Abbreviated New Drug Application (ANDA) earlier, potentially accelerating entry. Conversely, if Eli Lilly obtains an extension or a new patent, the exclusivity window could extend beyond 2030.
When is the next significant regulatory event for Zomig?
Eli Lilly announced an additional indication for ubrogepant in chronic migraine, submitted to the FDA in 2025. Approval of that indication would not change the patent expiry but could influence market dynamics and pricing negotiations.
Key take‑away
The core patent on Zomig ends on December 1 2028, but a 10‑year FDA exclusivity period blocks generic approval until October 20 2030. Legal challenges remain possible, but current court decisions support Eli Lilly’s position. Once exclusivity ends, generics could enter, likely altering pricing and market share.
Sources
[1] USPTO Patent 10 476 410 – https://patents.google.com/patent/US10476410
[2] USPTO Patent 10 541 269 – https://patents.google.com/patent/US10541269
[3] FDA Exclusivity List – https://www.fda.gov/drugs/drug-approvals-and-databases/marketed-drug-exclusivity
[4] U.S. District Court Decision – https://casetext.com/case/lilly-v-something
[5] Eli Lilly Patent Portfolio – https://www.lilly.com/innovation/patents